Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From resTORbio, Inc.
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
Repurposing a TORC1 inhibitor investigated in several cancer types at Novartis, resTORbio has initiated a second Phase III study of RTB101 to address immunosenescence in older adults. CMO Joan Mannick discusses R&D strategy in interview at IDWeek.